ArticleCancer medicine2025
Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register-Based Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non-small cell lung cancer (NSCLC). Preclinical studies suggest inflammatory and other mechanisms of analgesics affect the efficacy of EGFR TKIs. In this study, we aim to explore the outcomes of concurrent use of EGFR TKIs and analgesics, to provide clinical insight into analgesic treatment decisions.
methodsPatients (n = 1494) with EGFR TKI reimbursements (2011-2020) and data available in the Finnish Cancer Registry with concurrent analgesics purchases (nonsteroidal anti-inflammatory drugs [NSAID], acetaminophen, weak and strong opioids, strong opioids stratified by immunomodulatory properties) were identified. Overall survival (OS) and time-on-treatment (ToT) were analyzed using univariate and multivariate Cox models and Kaplan-Meier.
resultsIn multivariate analysis for ToT, weak and strong opioids were associated with inferior outcomes (HR 1.368, 95% CI 1.119-1.674, HR 1.454, 95% CI 1.276-1.656) compared to no analgesics, while NSAID and acetaminophen showed no association. Multivariate analysis for OS showed inferior survival among EGFR TKI-treated patients with weak (HR 1.290, 95% CI 1.043-1.595) and strong opioid (HR 1.690, 95% CI 1.471-1.940) purchases, while this was not seen with NSAID. Compared to nonimmunomodulatory opioids, patients with immunomodulatory opioid purchases had unfavorable outcomes for both ToT (HR 1.448, 95% CI 1.148-1.826) and OS (HR 1.479, 95% CI 1.158-1.888).
conclusionsIn EGFR TKI-treated NSCLC, opioids are an independent risk factor for worse ToT and OS. The outcomes differed by immunomodulatory category of opioids, suggesting analgesics class can potentially have an impact on EGFR TKI effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.